Novo Nordisk recalls batches of diabetes drugs

October 25, 2013

Batches of Novo Nordisk's diabetes treatments NovoMix 30 FlexPen and Penfill are being recalled, the European Medicines Agency said on Friday.

"In the affected cartridges the level of insulin may vary between 50 percent and 150 percent of the labelled insulin units, which could lead to or hyperglycaemia," the agency said in a statement.

Only a small percentage of cartridges, 0.14 percent, contain the wrong amount, the Danish company said.

Patients whose products were labelled with numbers from the affected batches should "make an appointment with their doctor or nurse for switching treatment as soon as it is feasible," the EU regulator said.

A spokesperson for the company was not immediately available on Friday afternoon.

Novo Nordisk has almost half the global insulin market, which has grown rapidly in recent years following a rise in the number of people suffering from diabetes, estimated by the World Health Organisation to stand at around 347 million.

Explore further: Company decision to pull diabetes drug could add GBP9 million to NHS drugs bill

Related Stories

Novo Nordisk says to market improved insulin in 2013

December 23, 2010

Danish pharmaceutical company Novo Nordisk said Thursday it planned to put a new insulin product on the market by 2013 after tests showed advantages to the widely sold diabetes drug Lantus.

Diabetes drugs helps boost Novo Nordisk in Q2

August 9, 2012

(AP) — Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 29 percent in the second quarter of 2012, chiefly spurred by strong sales of its new diabetes drugs.

Danish Novo Nordisk profit surges

January 31, 2013

Danish pharmaceutical company Novo Nordisk A/S on Thursday reported a 23 percent growth in fourth-quarter net profit on strong sales of diabetic drugs and gave a positive outlook as regulators worldwide begin to approve its ...

Novo Nordisk US shares skid on drug review setback (Update)

February 11, 2013

Shares of Novo Nordisk tumbled Monday after the Danish drugmaker said U.S. regulators need a new study before they can finish their review of two diabetes treatments, a development that could delay approval for several years.

Recommended for you

New study reveals a novel protein linked to type 2 diabetes

August 16, 2016

Findings from Boston University School of Medicine (BUSM), which appear in eLife, provide a possible explanation as to why most people who are obese develop insulin resistance and type 2 diabetes. A minority of obese individuals, ...

Gene variant explains differences in diabetes drug response

August 9, 2016

The first results from a large international study of patients taking metformin, the world's most commonly used type 2 diabetes drug, reveal genetic differences among patients that may explain why some respond much better ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.